Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cheryl H. Waters

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Parkinsonism & Related Disorders|September 10, 2002
Treatment of advanced stage patients with Parkinson's diseaseCheryl H Waters
Current Treatment Options in Neurology|March 12, 2003
Corticobasal DegenerationPanida Piboolnurak, Cheryl H. Waters
Expert Review of Neurotherapeutics|June 7, 2013
Continuous dopaminergic delivery to minimize motor complications in Parkinson's diseaseBrenton A Wright, Cheryl H Waters
Expert Review of Neurotherapeutics|December 3, 2009
Current strategies in the treatment of Parkinson's disease and a personalized approach to managementNancy L Diaz, Cheryl H Waters
Journal of Neuro-Ophthalmology : the Official Journal of the North American Neuro-Ophthalmology Society|June 5, 2004
Eye movement abnormalities in a case of X-linked dystonia-Parkinsonism (lubag)Daniel D Esmaili, Richard A Shubin, Cheryl H Waters, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|April 13, 2004
Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled studyCheryl H Waters, Kapil D Sethi, Robert A Hauser, et al.
Parkinsonism & Related Disorders|May 18, 2013
Applause sign in clinically overlapping diseases: a case of TDP-43 proteinopathyDavid Arkadir, Paul E Greene, Cheryl H Waters, et al.
Clinical Neuropharmacology|January 30, 2023
The Clinical Development of Levodopa Inhalation PowderRobert A Hauser, Peter A LeWitt, Cheryl H Waters, et al.
Journal of Genetic Counseling|June 11, 2013
Knowledge of and interest in genetic results among Parkinson disease patients and caregiversKarina Sakanaka, Cheryl H Waters, Oren A Levy, et al.
Parkinsonism & Related Disorders|November 1, 2020
A 12-month, dose-level blinded safety and efficacy study of levodopa inhalation powder (CVT-301, Inbrija) in patients with Parkinson's diseaseEric S Farbman, Cheryl H Waters, Peter A LeWitt, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Parkinsonism & Related Disorders|September 10, 2002
Treatment of advanced stage patients with Parkinson's diseaseCheryl H Waters
Current Treatment Options in Neurology|March 12, 2003
Corticobasal DegenerationPanida Piboolnurak, Cheryl H. Waters
Expert Review of Neurotherapeutics|June 7, 2013
Continuous dopaminergic delivery to minimize motor complications in Parkinson's diseaseBrenton A Wright, Cheryl H Waters
Expert Review of Neurotherapeutics|December 3, 2009
Current strategies in the treatment of Parkinson's disease and a personalized approach to managementNancy L Diaz, Cheryl H Waters
Journal of Neuro-Ophthalmology : the Official Journal of the North American Neuro-Ophthalmology Society|June 5, 2004
Eye movement abnormalities in a case of X-linked dystonia-Parkinsonism (lubag)Daniel D Esmaili, Richard A Shubin, Cheryl H Waters, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|April 13, 2004
Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled studyCheryl H Waters, Kapil D Sethi, Robert A Hauser, et al.
Parkinsonism & Related Disorders|May 18, 2013
Applause sign in clinically overlapping diseases: a case of TDP-43 proteinopathyDavid Arkadir, Paul E Greene, Cheryl H Waters, et al.
Clinical Neuropharmacology|January 30, 2023
The Clinical Development of Levodopa Inhalation PowderRobert A Hauser, Peter A LeWitt, Cheryl H Waters, et al.
Journal of Genetic Counseling|June 11, 2013
Knowledge of and interest in genetic results among Parkinson disease patients and caregiversKarina Sakanaka, Cheryl H Waters, Oren A Levy, et al.
Parkinsonism & Related Disorders|November 1, 2020
A 12-month, dose-level blinded safety and efficacy study of levodopa inhalation powder (CVT-301, Inbrija) in patients with Parkinson's diseaseEric S Farbman, Cheryl H Waters, Peter A LeWitt, et al.
Pageof 3